Herpesvirus entry mediator regulates hypoxiainducible factor-1α and erythropoiesis in mice

Journal of Clinical Investigation

Volumn 121, Issue 12, 2011, Pages 4810-4819

  Sakoda, Yukimi ^a   Anand, Sudarshan ^b   Zhao, Yuming ^a   Park, Jang June ^a   Liu, Yingjia ^a   Kuramasu, Atsuo ^a,c   Van Rooijen, Nico ^d   Chen, Ling ^e   Strome, Scott E ^a,e   Hancock, Wayne W ^f   Chen, Lieping ^b   Tamada, Koji ^a,c,e  

^a UNIVERSITY OF MARYLAND   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLODRONIC ACID; ERYTHROPOIETIN; HERPESVIRUS ENTRY MEDIATOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HM3.30; UNCLASSIFIED DRUG;

ANEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; ERYTHROBLAST; ERYTHROPOIESIS; FEMALE; FLOW CYTOMETRY; IN VIVO STUDY; MACROPHAGE; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; OXYGEN TENSION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL HYPOXIA; ERYTHROPOIESIS; ERYTHROPOIETIN; FEMALE; GENE EXPRESSION PROFILING; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; KIDNEY; MACROPHAGES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NITRIC OXIDE; OXYGEN; RADIATION CHIMERA; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 14; SIGNAL TRANSDUCTION;

EID: 84055199903     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI57332     Document Type: Article

References (54)

1. Fisher JW. Erythropoietin: physiology and pharmacology update. Exp Biol Med (Maywood). 2003; 228(1):1-14. (Pubitemid 36077622)
2. Jelkmann W. Molecular biology of erythropoietin. Intern Med. 2004;43(8):649-659. (Pubitemid 39264162)
3. Fandrey J. Oxygen-dependent and tissue-specific regulation of erythropoietin gene expression. Am J Physiol Regul Integr Comp Physiol. 2004;286(6):R977-R988. (Pubitemid 38661383)
4. Schofield CJ, Ratcliffe PJ. Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol. 2004; 5(5):343-354. (Pubitemid 38579472)
5. Webb JD, Coleman ML, Pugh CW. Hypoxia, hypoxiainducible factors (HIF), HIF hydroxylases and oxygen sensing. Cell Mol Life Sci. 2009;66(22):3539-3554.
6. Ivan M, et al. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science. 2001;292(5516):464-468. (Pubitemid 32335941)
7. Jaakkola P, et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science. 2001; 292(5516):468-472. (Pubitemid 32335942)
8. Yu F, White SB, Zhao Q, Lee FS. HIF-1alpha binding to VHL is regulated by stimulus-sensitive proline hydroxylation. Proc Natl Acad Sci U S A. 2001; 98(17):9630-9635. (Pubitemid 32769354)
9. Mahon PC, Hirota K, Semenza GL. FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev. 2001;15(20):2675-2686. (Pubitemid 32988878)
10. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003;3(10):721-732. (Pubitemid 37328811)
11. Dehne N, Brune B. HIF-1 in the inflammatory microenvironment. Exp Cell Res. 2009;315(11):1791-1797.
12. Rius J, et al. NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha. Nature. 2008;453(7196):807- 811. (Pubitemid 351793778)
13. Zhou J, Brune B. Cytokines and hormones in the regulation of hypoxia inducible factor-1alpha (HIF- 1alpha). Cardiovasc Hematol Agents Med Chem. 2006; 4(3):189-197. (Pubitemid 44027709)
14. Huang LE, Bunn HF. Hypoxia-inducible factor and its biomedical relevance. J Biol Chem. 2003; 278(22):19575-19578. (Pubitemid 36799137)
15. Berchner-Pfannschmidt U, Tug S, Kirsch M, Fandrey J. Oxygen-sensing under the influence of nitric oxide. Cell Signal. 2010;22(3):349-356.
16. Brune B, Zhou J. Nitric oxide and superoxide: interference with hypoxic signaling. Cardiovasc Res. 2007; 75(2):275-282. (Pubitemid 46961919)
17. Li F, et al. Regulation of HIF-1alpha stability through S-nitrosylation. Mol Cell. 2007;26(1):63-74.
18. Kasuno K, et al. Nitric oxide induces hypoxia-inducible factor 1 activation that is dependent on MAPK and phosphatidylinositol 3-kinase signaling. J Biol Chem. 2004;279(4):2550-2558.
19. Murphy TL, Murphy KM. Slow down and survive: Enigmatic immunoregulation by BTLA and HVEM. Annu Rev Immunol. 2010;28:389-411.
20. Marsters SA, Ayres TM, Skubatch M, Gray CL, Rothe M, Ashkenazi A. Herpesvirus entry mediator, a member of the tumor necrosis factor receptor (TNFR) family, interacts with members of the TNFR-associated factor family and activates the transcription factors NF-kappaB and AP-1. J Biol Chem. 1997;272(22):14029-14032. (Pubitemid 27232801)
21. Harrop JA, et al. Herpesvirus entry mediator ligand (HVEM-L), a novel ligand for HVEM/TR2, stimulates proliferation of T cells and inhibits HT29 cell growth. J Biol Chem. 1998;273(42):27548-27556. (Pubitemid 28500476)
22. Tamada K, et al. Modulation of T-cell-mediated immunity in tumor and graft-versus-host disease models through the LIGHT co-stimulatory pathway. Nat Med. 2000;6(3):283-289. (Pubitemid 30148620)
23. Tamada K, et al. LIGHT, a TNF-like molecule, costimulates T cell proliferation and is required for dendritic cell-mediated allogeneic T cell response. J Immunol. 2000;164(8):4105-4110. (Pubitemid 30215066)
24. Heo SK, et al. LIGHT enhances the bactericidal activity of human monocytes and neutrophils via HVEM. J Leukoc Biol. 2006;79(2):330-338.
25. Xu Y, et al. Selective targeting of the LIGHT-HVEM costimulatory system for the treatment of graftversus- host disease. Blood. 2007;109(9):4097-4104. (Pubitemid 46641766)
26. Jelkmann W. Erythropoietin: structure, control of production, and function. Physiol Rev. 1992; 72(2):449-489.
27. Weidemann A, Johnson RS. Nonrenal regulation of EPO synthesis. Kidney Int. 2009;75(7):682-688.
28. Montgomery RI, Warner MS, Lum BJ, Spear PG. Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family. Cell. 1996;87(3):427-436. (Pubitemid 26374317)
29. Van Rooijen N, Sanders A. Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J Immunol Methods. 1994;174(1-2):83-93.
30. Zeisberger SM, Odermatt B, Marty C, Zehnder- Fjallman AH, Ballmer-Hofer K, Schwendener RA. Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach. Br J Cancer. 2006;95(3):272-281. (Pubitemid 44187587)
31. MacMicking J, Xie QW, Nathan C. Nitric oxide and macrophage function. Annu Rev Immunol. 1997; 15:323-350. (Pubitemid 27169284)
32. Nizet V, Johnson RS. Interdependence of hypoxic and innate immune responses. Nat Rev Immunol. 2009; 9(9):609-617.
33. Peyssonnaux C, et al. HIF-1alpha expression regulates the bactericidal capacity of phagocytes. J Clin Invest. 2005;115(7):1806-1815. (Pubitemid 40979719)
34. Boutin AT, et al. Epidermal sensing of oxygen is essential for systemic hypoxic response. Cell. 2008; 133(2):223-234. (Pubitemid 351508305)
35. Keswani SC, Bosch-Marce M, Reed N, Fischer A, Semenza GL, Hoke A. Nitric oxide prevents axonal degeneration by inducing HIF-1-dependent expression of erythropoietin. Proc Natl Acad Sci U S A. 2011;108(12):4986-4990.
36. Ohigashi T, Brookins J, Fisher JW. Interaction of nitric oxide and cyclic guanosine 3&πριμε;,5&πριμε;- monophosphate in erythropoietin production. J Clin Invest. 1993;92(3):1587-1591. (Pubitemid 23273942)
37. Lacombe C, et al. Peritubular cells are the site of erythropoietin synthesis in the murine hypoxic kidney. J Clin Invest. 1988;81(2):620-623. (Pubitemid 18075261)
38. Semenza GL, Koury ST, Nejfelt MK, Gearhart JD, Antonarakis SE. Cell-type-specific and hypoxiainducible expression of the human erythropoietin gene in transgenic mice. Proc Natl Acad Sci U S A. 1991; 88(19):8725-8729. (Pubitemid 21915429)
39. Maxwell PH, et al. Identification of the renal erythropoietin- producing cells using transgenic mice. Kidney Int. 1993;44(5):1149-1162. (Pubitemid 23316488)
40. Obara N, Suzuki N, Kim K, Nagasawa T, Imagawa S, Yamamoto M. Repression via the GATA box is essential for tissue-specific erythropoietin gene expression. Blood. 2008;111(10):5223-5232.
41. Da Silva JL, et al. Tumor cells are the site of erythropoietin synthesis in human renal cancers associated with polycythemia. Blood. 1990;75(3):577-582.
42. Zhou J, Fandrey J, Schumann J, Tiegs G, Brune B. NO and TNF-alpha released from activated macrophages stabilize HIF-1alpha in resting tubular LLC-PK1 cells. Am J Physiol Cell Physiol. 2003; 284(2):C439-C446.
43. Scortegagna M, et al. HIF-2alpha regulates murine hematopoietic development in an erythropoietindependent manner. Blood. 2005;105(8):3133-3140.
44. Rankin EB, et al. Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo. J Clin Invest. 2007;117(4):1068-1077. (Pubitemid 46556763)
45. Kapitsinou PP, et al. Hepatic HIF-2 regulates erythropoietic responses to hypoxia in renal anemia. Blood. 2010;116(16):3039-3048.
46. Ang SO, et al. Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nat Genet. 2002;32(4):614-621. (Pubitemid 35435173)
47. Flygare J, Rayon Estrada V, Shin C, Gupta S, Lodish HF. HIF1alpha synergizes with glucocorticoids to promote BFU-E progenitor self-renewal. Blood. 2011;117(12):3435-3444.
48. Henke M, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebocontrolled trial. Lancet. 2003;362(9392):1255-1260. (Pubitemid 37324251)
49. Leyland-Jones B, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol. 2005;23(25):5960-5972.
50. Wright JR, et al. Randomized, double-blind, placebo- controlled trial of erythropoietin in non-smallcell lung cancer with disease-related anemia. J Clin Oncol. 2007;25(9):1027-1032. (Pubitemid 46596751)
51. Dicato M, Plawny L. Erythropoietin in cancer patients: pros and cons. Curr Opin Oncol. 2010; 22(4):307-311.
52. Rizzo JD, et al. American Society of Hematology/ American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Blood. 2010;116(20):4045-4059.
53. Fishbane S. Recombinant human erythropoietin: has treatment reached its full potential? Semin Dial. 2006;19(1):1-4. (Pubitemid 43479005)
54. Zhao Y, et al. Activation of keratinocyte protein kinase C zeta in psoriasis plaques. J Invest Dermatol. 2008;128(9):2190-2197.